Linezolid pharmacokinetics in patients with acute renal failure undergoing continuous venovenous hemodiafiltration.

  title={Linezolid pharmacokinetics in patients with acute renal failure undergoing continuous venovenous hemodiafiltration.},
  author={Esther Carcelero and Dolors Soy and Laura Guerrero and Esteban Poch and J. Fern{\'a}ndez and Pedro Filipe Martins de Castro and Jos{\'e} Paulo Ribas},
  journal={Journal of clinical pharmacology},
  volume={52 9},
A renal failure (ARF) is relatively common in the intensive care unit (ICU) setting, and it is associated with an increased mortality (23%-52%). Some patients with ARF will need renal replacement therapy. A high percentage of critically ill patients with ARF do not tolerate intermittent hemodialysis because of hemodynamic instability. Continuous renal replacement therapy (CRRT) runs continuously over a 24-hour period (unlike conventional hemodialysis, which generally lasts about 4 hours and is… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 17 references

The impact of continuous renal replacement therapy on drug therapy.

Clinical pharmacology and therapeutics • 2009
View 4 Excerpts
Highly Influenced

Clearance of linezolid via continuous venovenous hemodiafiltration.

American journal of kidney diseases : the official journal of the National Kidney Foundation • 2006
View 4 Excerpts
Highly Influenced

Computation of model-independent pharmacokinetic parameters during multiple dosing.

Journal of pharmaceutical sciences • 1983
View 3 Excerpts
Highly Influenced

[Measuring linezolid in biological fluids using high-efficiency liquid chromatography].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria • 2010
View 2 Excerpts

Similar Papers

Loading similar papers…